STOCK TITAN

Corbus Pharmaceuticals Holdings (CRBP) Stock News

CRBP NASDAQ

Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.

Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.

Rhea-AI Summary

Corbus Pharmaceuticals Holdings (CRBP) presented Phase 1b CANYON-1 obesity data showing 5% mean weight loss with CRB-913 at 12 weeks. The placebo-controlled study enrolled 254 non-diabetic adults with obesity. Mean weight loss was 2.8%, 3.3% and 5.0% at 20 mg, 40 mg and 60 mg, respectively, versus 0.0% with placebo; all comparisons had p<0.0001. Waist circumference and body mass index also declined, with no weight-loss plateau observed.

Safety results included no serious treatment-related adverse events and no serious or severe psychiatric events. However, four participants had serious treatment-emergent events, meaning events arising during treatment regardless of cause. Adverse-event discontinuations were 8.3% across all cohorts, including placebo, and 12.9% at 60 mg. Corbus plans FDA discussions on the data and development plans and is evaluating potential combinations with GLP-1 therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported a third-quarter 2026 net loss of approximately $37.8 million while advancing its cancer and obesity trials. The loss compared with approximately $23.3 million a year earlier; loss per share narrowed to $1.81 from $1.90. Operating expenses rose to approximately $38.8 million, primarily reflecting a $15.0 million CSPC development milestone.

First-patient dosing began in September in the TEMPO-1 registrational study of sutantatug envedotin for previously treated oropharyngeal cancer. In CANYON-1, CRB-913 produced mean weight loss of 5% after 12 weeks at 60 mg daily, with no plateau observed at any dose. Corbus expects first-line cancer combination data in Q1 2027 and plans FDA discussions on CRB-913 development. Cash, cash equivalents and investments totaled $115.3 million at September 30, which the company expects to fund operations into 2028 under current plans and planned expenditures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.65%
Tags
-
Rhea-AI Summary

Corbus Pharmaceuticals Holdings (CRBP) announced that CEO Yuval Cohen will present a corporate overview and meet investors at upcoming healthcare conferences.

The schedule includes Guggenheim on November 9, 2026, at 8:00am EST; Jefferies on November 18 at 9:00am GMT; and Evercore on December 1 at 10:25am EST. Guggenheim features a presentation, while Jefferies and Evercore feature fireside chats. All three include one-on-one investor meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.89%
Tags
conferences
Rhea-AI Summary

Corbus Pharmaceuticals (CRBP) will present late-breaking CRB-913 Canyon-1 Phase 1B study data at Obesity Week 2026 on November 15, 2026.

Harold Bays will present the poster on efficacy, safety and tolerability from 2:30–3:30 p.m. ET at the Gaylord National Resort & Convention Center in National Harbor, Maryland.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (CRBP) dosed the first patient in its TEMPO-1 registrational study of CRB-701 for previously treated oropharyngeal cancer. The randomized, controlled study is designed for 250 patients with second-line or later oropharyngeal squamous cell carcinoma. It compares CRB-701 with an investigator’s choice of capecitabine, cetuximab or docetaxel. Objective response rate, a measure of tumor shrinkage, is the primary endpoint intended to support potential accelerated approval; overall survival is intended to support potential full approval.

The FDA allowed TEMPO-1 to proceed based on results from an ongoing Phase 1/2 study. Among patients with second-line or later disease treated at the 3.6 mg/kg dose, CRB-701 produced a confirmed objective response rate of 42.9%, median response duration of 6.3 months and median progression-free survival of 5.6 months (ongoing).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (CRBP) reported positive topline Phase 1b data showing 5% mean weight loss with oral CRB-913 after 12 weeks.

The 16-week double-blind, placebo-controlled CANYON-1 trial enrolled 254 obese, non-diabetic adults across three once-daily dose cohorts (20, 40, 60 mg) and placebo. At week 12, least-squares mean percent weight change was 0.0% for placebo and 2.8%, 3.3% and 5.0% for the 20, 40 and 60 mg groups, all placebo-adjusted and statistically significant (p<0.0001). Among participants receiving 60 mg who completed treatment, 44.4% lost at least 5% of baseline weight, 6.7% lost more than 7.5%, and the maximum loss was 13.4%, with no plateau observed.

CRB-913 was generally well tolerated, with discontinuations due to adverse events of 3.1%-13.1%, no serious or severe psychiatric events, one transient moderate depressive symptom among 188 treated participants, and mostly mild, non–dose-dependent gastrointestinal events. Corbus plans a Phase 2 monotherapy study in the first half of 2027 and will present detailed data at ObesityWeek® 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
Rhea-AI Summary

Corbus Pharmaceuticals (CRBP) will host a virtual conference call and webcast on Monday, September 14, 2026, at 8:00 a.m. EDT to discuss topline data from CANYON-1, a Phase 1b study of obesity candidate CRB-913.

The 16-week double-blind, placebo-controlled, dose-ranging trial enrolls 240 obese, non-diabetic adults across multiple U.S. sites, with once-daily oral doses of 20 mg, 40 mg, or 60 mg CRB-913 versus placebo. All CRB-913 participants start at 20 mg/day and titrate to their assigned dose, receive 12 weeks of treatment, and then have a four-week safety follow-up. Investigator Harold Bays, M.D., will join as a guest speaker, and a replay will be available on the Corbus website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences clinical trial
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported that its Compensation Committee approved inducement equity awards for new Chief Medical Officer Leonardo Nicacio, effective August 16, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards were granted outside Corbus’ stockholder-approved equity plans as a material inducement to his employment.

The package includes a nonstatutory stock option for up to 191,676 shares of common stock at an exercise price of $10.09, with a ten-year term, vesting 25% on the first anniversary and the remaining 75% in equal monthly installments over 36 months, subject to continued service. It also includes 58,333 restricted stock units vesting in four equal annual installments, each RSU converting into one share upon vesting, contingent on continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q2 2026 net loss of approximately $35.0 million, or $1.81 per share, versus $17.7 million, or $1.44 per share, a year earlier. Operating expenses rose to about $36.2 million from $19.2 million, mainly due to higher clinical costs including a $10.0 million milestone payment under the CRB-701 license.

Corbus obtained FDA clearance for TEMPO-1, a Phase 3 registrational study (n=250) of CRB-701 in second-line oropharyngeal squamous cell carcinoma, with enrollment expected to start in September 2026. The company completed last patient last visit in the 240-patient CANYON-1 Phase 1b obesity study of CRB-913 and plans topline data in September 2026. Leadership was strengthened with a new Chief Medical Officer, Chief Business Officer, and Board member. Corbus held $117.9 million in cash, cash equivalents, and investments as of June 30, 2026, which it expects to fund operations into 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported that the last patient has completed the final clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping topline data on track for September 2026.

CANYON-1 is a 16‑week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adults in the U.S., testing once-daily oral doses of 20 mg, 40 mg and 60 mg versus placebo with a dose-titration regimen and a 4‑week safety follow-up. CRB-913 is described as a highly peripherally restricted CB1 inverse agonist, aiming to offer an orthogonal, non-incretin oral approach to weight loss. The study follows Phase 1a data indicating differentiated GI tolerability versus GLP‑1 therapies and preclinical mouse data showing approximately 15-fold lower brain penetration than the CB1 inverse agonist monlunabant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
none

FAQ

What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?

Corbus Pharmaceuticals Holdings (CRBP) last closed at $2.75.

What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?

The market cap of Corbus Pharmaceuticals Holdings (CRBP) is approximately $56.6M.